Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 1997;28:2382-2389

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brass, L. M.
Right arrow Articles by Radford, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brass, L. M.
Right arrow Articles by Radford, M.

(Stroke. 1997;28:2382-2389.)
© 1997 American Heart Association, Inc.


Articles

Warfarin Use Among Patients With Atrial Fibrillation

Lawrence M. Brass, MD; Harlan M. Krumholz, MD; Jeanne M. Scinto, PhD, MPH; Martha Radford, MD

From the Center for Outcomes Research and Evaluation, Yale–New Haven Hospital, New Haven, Conn (L.M.B., H.M.K.); Neurology Service, VA Connecticut Healthcare System, West Haven (L.M.B.); Yale Stroke Program, Department of Neurology (L.M.B.), Section of Chronic Disease Epidemiology, School of Epidemiology and Public Health (L.M.B., H.M.K.), and Department of Cardiology (H.M.K.), Yale University School of Medicine, New Haven, Conn; Connecticut Peer Review Organization, Middletown (L.M.B., H.M.K., J.M.S., M.R.); and Department of Cardiology (M.R.), University of Connecticut Health Sciences Center, Farmington.

Correspondence to Lawrence M. Brass, MD, Yale Stroke Program, Department of Neurology, LCI-700, Yale University School of Medicine, 15 York St, PO Box 208018, New Haven, CT 06520-8018. E-mail lawrence.brass{at}yale.edu

Background and Purpose Warfarin reduces the rate of stroke among patients with atrial fibrillation. We sought to determine warfarin use within a population sample of elderly patients with atrial fibrillation.

Methods The Connecticut Peer Review Organization conducted a chart review of Medicare patients aged >=65 years with a history of atrial fibrillation before a hospitalization during the first 6 months of 1994.

Results Among 488 patients (308 women; 457 white; 173 aged >=85 years), 38% (184/488) had a relative contraindication to anticoagulation (history of bleeding, dementia, alcohol use, falls, cancer, or the need for nonsteroidal anti-inflammatory drugs). Among the remaining patients (with known atrial fibrillation, but without a contraindication), only 38% (117/304) had been prescribed warfarin. Of those not prescribed warfarin, 63% (117/187) were also not taking aspirin. There were 272 patients with at least one additional vascular risk factor and no contraindication to anticoagulation. Among these patients at moderate to high risk for stroke, anticoagulation had been prescribed in 40% (109/272). Overall, among those not prescribed warfarin, 58% (95/163) were not taking aspirin. Patients admitted with a stroke were more likely to be significantly underanticoagulated (with international normalized ratio <1.5) (43.5% versus 20.9% for those without stroke; P<.005). Anticoagulation was most effective for those with an international normalized ratio >=2.0.

Conclusions Warfarin anticoagulation with atrial fibrillation, even among "ideal" candidates, appears dramatically underutilized. In addition, among those prescribed warfarin, patients are often undertreated. Increased warfarin use among patients with atrial fibrillation represents an excellent opportunity for stroke prevention in the elderly.


Key Words: anticoagulants • atrial fibrillation • stroke prevention • warfarin




This article has been cited by other articles:


Home page
Circ Cardiovasc Qual OutcomesHome page
D. E. Singer, Y. Chang, M. C. Fang, L. H. Borowsky, N. K. Pomernacki, N. Udaltsova, and A. S. Go
Should Patient Characteristics Influence Target Anticoagulation Intensity for Stroke Prevention in Nonvalvular Atrial Fibrillation?: The ATRIA Study
Circ Cardiovasc Qual Outcomes, July 1, 2009; 2(4): 297 - 304.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. S. Kanderian, A. M. Gillinov, G. B. Pettersson, E. Blackstone, and A. L. Klein
Success of Surgical Left Atrial Appendage Closure: Assessment by Transesophageal Echocardiography
J. Am. Coll. Cardiol., September 9, 2008; 52(11): 924 - 929.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
D. E. Singer, G. W. Albers, J. E. Dalen, M. C. Fang, A. S. Go, J. L. Halperin, G. Y. H. Lip, and W. J. Manning
Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 546S - 592S.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
E. A. Nutescu
ASHP Therapeutic Position Statement on Antithrombotic Therapy in Chronic Atrial Fibrillation
Am. J. Health Syst. Pharm., November 1, 2007; 64(21): 2281 - 2291.
[Full Text] [PDF]


Home page
QJMHome page
N. Anderson, R. Fuller, and N. Dudley
'Rules of thumb' or reflective practice? Understanding senior physicians' decision-making about anti-thrombotic usage in atrial fibrillation
QJM, May 1, 2007; 100(5): 263 - 269.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. B. Sick, G. Schuler, K. E. Hauptmann, E. Grube, S. Yakubov, Z. G. Turi, G. Mishkel, S. Almany, and D. R. Holmes
Initial Worldwide Experience With the WATCHMAN Left Atrial Appendage System for Stroke Prevention in Atrial Fibrillation
J. Am. Coll. Cardiol., April 3, 2007; 49(13): 1490 - 1495.
[Abstract] [Full Text] [PDF]


Home page
Age AgeingHome page
A. Rash, T. Downes, R. Portner, W. W. Yeo, N. Morgan, and K. S. Channer
A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO)
Age Ageing, March 1, 2007; 36(2): 151 - 156.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
N. Dagres, R. Nieuwlaat, P. E. Vardas, D. Andresen, S. Levy, S. Cobbe, D. Th. Kremastinos, G. Breithardt, D. V. Cokkinos, and H. J.G.M. Crijns
Gender-Related Differences in Presentation, Treatment, and Outcome of Patients With Atrial Fibrillation in Europe: A Report From the Euro Heart Survey on Atrial Fibrillation
J. Am. Coll. Cardiol., February 6, 2007; 49(5): 572 - 577.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
L Kalra, G Y H Lip, and on behalf of the Guideline Development Group for t
Antithrombotic treatment in atrial fibrillation
Heart, January 1, 2007; 93(1): 39 - 44.
[Full Text] [PDF]


Home page
Eur Heart JHome page
L. Friberg, N. Hammar, M. Ringh, H. Pettersson, and M. Rosenqvist
Stroke prophylaxis in atrial fibrillation: who gets it and who does not?: Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study)
Eur. Heart J., August 2, 2006; 27(16): 1954 - 1964.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al.
Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline.
Circulation, June 20, 2006; 113(24): e873 - e923.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al.
Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline.
Stroke, June 1, 2006; 37(6): 1583 - 1633.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
E. M. Hylek, J. D'Antonio, C. Evans-Molina, C. Shea, L. E. Henault, and S. Regan
Translating the Results of Randomized Trials into Clinical Practice: The Challenge of Warfarin Candidacy Among Hospitalized Elderly Patients With Atrial Fibrillation
Stroke, April 1, 2006; 37(4): 1075 - 1080.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
Y. Miyasaka, M. E. Barnes, B. J. Gersh, S. S. Cha, J. B. Seward, K. R. Bailey, T. Iwasaka, and T. S.M. Tsang
Time Trends of Ischemic Stroke Incidence and Mortality in Patients Diagnosed With First Atrial Fibrillation in 1980 to 2000: Report of a Community-Based Study
Stroke, November 1, 2005; 36(11): 2362 - 2366.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. H. Ostermayer, M. Reisman, P. H. Kramer, R. V. Matthews, W. A. Gray, P. C. Block, H. Omran, A. L. Bartorelli, P. Della Bella, C. Di Mario, et al.
Percutaneous Left Atrial Appendage Transcatheter Occlusion (PLAATO System) to Prevent Stroke in High-Risk Patients With Non-Rheumatic Atrial Fibrillation: Results From the International Multi-Center Feasibility Trials
J. Am. Coll. Cardiol., July 5, 2005; 46(1): 9 - 14.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
D. Garcia, S. Regan, M. Crowther, R. A. Hughes, and E. M. Hylek
Warfarin Maintenance Dosing Patterns in Clinical Practice: Implications for Safer Anticoagulation in the Elderly Population
Chest, June 1, 2005; 127(6): 2049 - 2056.
[Abstract] [Full Text] [PDF]


Home page
Int J Qual Health CareHome page
M. J. Lim, C. Roychoudhury, P. L. Baker, E. Bossone, and R. H. Mehta
Differences in quality of care among patients hospitalized with atrial fibrillation as primary or secondary cause for admission
Int. J. Qual. Health Care, June 1, 2005; 17(3): 255 - 258.
[Abstract] [Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
R Katira, A Chauhan, and R S More
Direct thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillation
Postgrad. Med. J., June 1, 2005; 81(956): 370 - 375.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. G. Hackam, A. Kopp, and D. A. Redelmeier
Prognostic Implications of Warfarin Cessation After Major Trauma: A Population-Based Cohort Analysis
Circulation, May 3, 2005; 111(17): 2250 - 2256.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
M. W. Reynolds, K. Fahrbach, O. Hauch, G. Wygant, R. Estok, C. Cella, and L. Nalysnyk
Warfarin Anticoagulation and Outcomes in Patients With Atrial Fibrillation: A Systematic Review and Metaanalysis
Chest, December 1, 2004; 126(6): 1938 - 1945.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
R. Teng, T. C. Sarich, U. G. Eriksson, J. E. Hamer, S. Gillette, K.-M. Schutzer, G. F. Carlson Jr, and P. R. Kowey
A Pharmacokinetic Study of the Combined Administration of Amiodarone and Ximelagatran, an Oral Direct Thrombin Inhibitor
J. Clin. Pharmacol., September 1, 2004; 44(9): 1063 - 1071.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
D. E. Singer, G. W. Albers, J. E. Dalen, A. S. Go, J. L. Halperin, and W. J. Manning
Antithrombotic Therapy in Atrial Fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest, September 1, 2004; 126(3_suppl): 429S - 456S.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
S. Volpato, C. Maraldi, A. Ble, M. Ranzini, A. Rita Atti, L. J. Dominguez, M. Barbagallo, R. Fellin, and G. Zuliani
Prescription of Antithrombotic Therapy in Older Patients Hospitalized for Transient Ischemic Attack and Ischemic Stroke: The GIFA Study
Stroke, April 1, 2004; 35(4): 913 - 917.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
J S Steinberg
Atrial fibrillation: an emerging epidemic?
Heart, March 1, 2004; 90(3): 239 - 240.
[Full Text] [PDF]


Home page
Eur Heart J SupplHome page
G.Q. Villani, M. Piepoli, P.E. Villani, and A. Capucci
Anticoagulation in atrial fibrillation: what is certain and what is to come
Eur. Heart J. Suppl., September 1, 2003; 5(suppl_H): H45 - H50.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
R. S. Stafford and D. C. Radley
The underutilization of cardiacmedications of proven benefit, 1990 to 2002
J. Am. Coll. Cardiol., January 1, 2003; 41(1): 56 - 61.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
T. M. Koelling and K. A. Eagle
Measuring quality of outpatient cardiovascular care
J. Am. Coll. Cardiol., January 1, 2003; 41(1): 69 - 72.
[Full Text] [PDF]


Home page
BMJHome page
P J Devereaux, D. R Anderson, M. J Gardner, W. Putnam, G. J Flowerdew, B. F Brownell, S. Nagpal, J. L Cox, and T. Fahey
Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study Commentary: Varied preferences reflect the reality of clinical practice
BMJ, November 24, 2001; 323(7323): 1218 - 1218.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
D. McCormick, J. H. Gurwitz, R. J. Goldberg, R. Becker, J. P. Tate, A. Elwell, and M. J. Radford
Prevalence and Quality of Warfarin Use for Patients With Atrial Fibrillation in the Long-term Care Setting
Arch Intern Med, November 12, 2001; 161(20): 2458 - 2463.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
C. Wehinger, C. Stollberger, T. Langer, B. Schneider, and J. Finsterer
Evaluation of Risk Factors for Stroke/Embolism and of Complications Due to Anticoagulant Therapy in Atrial Fibrillation
Stroke, October 1, 2001; 32(10): 2246 - 2252.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
N. Shinokawa, T. Hirai, S. Takashima, T. Kameyama, K. Nakagawa, H. Asanoi, and H. Inoue
A Transesophageal Echocardiographic Study on Risk Factors for Stroke in Elderly Patients With Atrial Fibrillation : A Comparison With Younger Patients
Chest, September 1, 2001; 120(3): 840 - 846.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
T. Sappok, A. Faulstich, E. Stuckert, H. Kruck, P. Marx, and H.-C. Koennecke
Compliance With Secondary Prevention of Ischemic Stroke: A Prospective Evaluation
Stroke, August 1, 2001; 32(8): 1884 - 1889.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
G. W. Albers, J. E. Dalen, A. Laupacis, W. J. Manning, P. Petersen, and D. E. Singer
Antithrombotic Therapy in Atrial Fibrillation
Chest, January 1, 2001; 119 (2009): 194S - 206S.
[Full Text] [PDF]


Home page
BMJHome page
D A Fitzmaurice, J Mant, E T Murray, F D R Hobbs, N. Oswald, M D Oliver, A. Ono, G. Bellelli, A. Bianchetti, and M. Trabucchi
Anticoagulation to prevent stroke in atrial fibrillation
BMJ, November 4, 2000; 321(7269): 1156 - 1156.
[Full Text]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
K N Vemmos, M L Bots, P K Tsibouris, V P Zis, C E Takis, D E Grobbee, and S Stamatelopoulos
Prognosis of stroke in the south of Greece: 1 year mortality, functional outcome and its determinants: the Arcadia Stroke Registry
J. Neurol. Neurosurg. Psychiatry, November 1, 2000; 69(5): 595 - 600.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
L. B. Goldstein, J. Bian, G. P. Samsa, A. J. Bonito, L. J. Lux, and D. B. Matchar
New Transient Ischemic Attack and Stroke: Outpatient Management by Primary Care Physicians
Arch Intern Med, October 23, 2000; 160(19): 2941 - 2946.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
R. G. Holloway, C. Benesch, and S. R. Rush
Stroke prevention: Narrowing the evidence-practice gap
Neurology, May 23, 2000; 54(10): 1899 - 1906.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
L. Kalra, G. Yu, I. Perez, A. Lakhani, and N. Donaldson
Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness
BMJ, May 6, 2000; 320(7244): 1236 - 1239.
[Abstract] [Full Text]


Home page
StrokeHome page
B. F. Gage, M. Boechler, A. L. Doggette, G. Fortune, G. C. Flaker, M. W. Rich, and M. J. Radford
Adverse Outcomes and Predictors of Underuse of Antithrombotic Therapy in Medicare Beneficiaries With Chronic Atrial Fibrillation
Stroke, April 1, 2000; 31(4): 822 - 827.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
W. N. Kernan, C. M. Viscoli, L. M. Brass, R. W. Makuch, P. M. Sarrel, and R. I. Horwitz
Blood Pressure Exceeding National Guidelines Among Women After Stroke
Stroke, February 1, 2000; 31(2): 415 - 419.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
T. Hillen, R. Dundas, E. Lawrence, J. A. Stewart, A. G. Rudd, and C. D. A. Wolfe
Antithrombotic and Antihypertensive Management 3 Months After Ischemic Stroke : A Prospective Study in an Inner City Population
Stroke, February 1, 2000; 31(2): 469 - 475.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
T. J. Bungard, W. A. Ghali, K. K. Teo, F. A. McAlister, and R. T. Tsuyuki
Why Do Patients With Atrial Fibrillation Not Receive Warfarin?
Arch Intern Med, January 10, 2000; 160(1): 41 - 46.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
J. Carlsson, S. Miketic, G. Dees, S. Haun, A. Cuneo, and U. Tebbe
Stroke prevention practices in patients with atrial fibrillation and pacemaker therapy: Evidence for under-use of anticoagulation
Europace, January 1, 2000; 2(2): 115 - 118.
[Abstract] [PDF]


Home page
StrokeHome page
L. B. Goldstein, L. A. Hey, and R. Laney
North Carolina Stroke Prevention and Treatment Facilities Survey : Statewide Availability of Programs and Services
Stroke, January 1, 2000; 31(1): 66 - 70.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
A. S. Go, E. M. Hylek, L. H. Borowsky, K. A. Phillips, J. V. Selby, and D. E. Singer
Warfarin Use among Ambulatory Patients with Nonvalvular Atrial Fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study
Ann Intern Med, December 21, 1999; 131(12): 927 - 934.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
J. L. Cox, N. Ad, and T. Palazzo
IMPACT OF THE MAZE PROCEDURE ON THE STROKE RATE IN PATIENTS WITH ATRIAL FIBRILLATION
J. Thorac. Cardiovasc. Surg., November 1, 1999; 118(5): 833 - 840.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
N M Al-Saady, O A Obel, and A J Camm
Left atrial appendage: structure, function, and role in thromboembolism
Heart, November 1, 1999; 82(5): 547 - 554.
[Abstract] [Full Text]


Home page
HeartHome page
D Deplanque, F Corea, C Arquizan, L Parnetti, J L Mas, V Gallai, D Leys, and the SAFE I Study Investigators
Stroke and atrial fibrillation: is stroke prevention treatment appropriate beforehand?
Heart, November 1, 1999; 82(5): 563 - 569.
[Abstract] [Full Text]


Home page
HeartHome page
I Perez, A Melbourn, and L Kalra
Use of antithrombotic measures for stroke prevention in atrial fibrillation
Heart, November 1, 1999; 82(5): 570 - 574.
[Abstract] [Full Text]


Home page
CMAJHome page
J. J. Caro, K. M. Flegel, M.-E. Orejuela, H. E. Kelley, J. L. Speckman, and K. Migliaccio-Walle
Anticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice
Can. Med. Assoc. J., September 1, 1999; 161(5): 493 - 497.
[Abstract] [Full Text] [PDF]


Home page
CMAJHome page
S. J. Connolly
Preventing stroke in atrial fibrillation: Why are so many eligible patients not receiving anticoagulant therapy?
Can. Med. Assoc. J., September 1, 1999; 161(5): 533 - 534.
[Full Text] [PDF]


Home page
Arch Intern MedHome page
N. L. Smith, B. M. Psaty, C. D. Furberg, R. White, J. A. C. Lima, A. B. Newman, and T. A. Manolio
Temporal Trends in the Use of Anticoagulants Among Older Adults With Atrial Fibrillation
Arch Intern Med, July 26, 1999; 159(14): 1574 - 1578.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
L. Kalra, I. Perez, and A. Melbourn
Risk Assessment and Anticoagulation for Primary Stroke Prevention in Atrial Fibrillation
Stroke, June 1, 1999; 30(6): 1218 - 1222.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
K. N. Vemmos, M. L. Bots, P. K. Tsibouris, V. P. Zis, D. E. Grobbee, G. S. Stranjalis, and S. Stamatelopoulos
Stroke Incidence and Case Fatality in Southern Greece : The Arcadia Stroke Registry
Stroke, February 1, 1999; 30(2): 363 - 370.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
L. M. Brass, H. M. Krumholz, J. D. Scinto, D. Mathur, and M. Radford
Warfarin Use Following Ischemic Stroke Among Medicare Patients With Atrial Fibrillation
Arch Intern Med, October 26, 1998; 158(19): 2093 - 2100.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
G. W. Albers
Choice of Antithrombotic Therapy for Stroke Prevention in Atrial Fibrillation: Warfarin, Aspirin, or Both?
Arch Intern Med, July 27, 1998; 158(14): 1487 - 1491.
[Full Text] [PDF]


Home page
StrokeHome page
L. A. Simons, J. McCallum, Y. Friedlander, and J. Simons
Risk Factors for Ischemic Stroke : Dubbo Study of the Elderly
Stroke, July 1, 1998; 29(7): 1341 - 1346.
[Abstract] [Full Text] [PDF]